Mitral valve prolapse
|Mitral valve prolapses|
|Classification and external resources|
In mitral valve prolapse, the leaflets of the mitral valve prolapse back into the left atrium.
Mitral valve prolapse (aka primary form of myxomatous degeneration of the mitral valve aka floppy mitral valve syndrome) is a valvular heart disease characterized by the displacement of an abnormally thickened mitral valve leaflet into the left atrium during systole. There are various types of MVP, broadly classified as classic and nonclassic. In its nonclassic form, MVP carries a low risk of complications. In severe cases of classic MVP, complications include mitral regurgitation, infective endocarditis, congestive heart failure, and, in rare circumstances, cardiac arrest, usually resulting in sudden death.
The condition was first described by John Brereton Barlow in 1966. In consequence, it may also be referred to as Barlow's Syndrome, and was subsequently termed mitral valve prolapse by J. Michael Criley.
The mitral valve, so named because of its resemblance to a bishop's mitre, is the heart valve that prevents the backflow of blood from the left ventricle into the left atrium of the heart. It is composed of two leaflets, one anterior and one posterior, that close when the left ventricle contracts.
Each leaflet is composed of three layers of tissue: the atrialis, fibrosa, and spongiosa. Patients with classic mitral valve prolapse have excess connective tissue that thickens the spongiosa and separates collagen bundles in the fibrosa. This is due to an excess of dermatan sulfate, a glycosaminoglycan. This weakens the leaflets and adjacent tissue, resulting in increased leaflet area and elongation of the chordae tendineae. Elongation of the chordae tendineae often causes rupture, commonly to the chordae attached to the posterior leaflet. Advanced lesions—also commonly involving the posterior leaflet—lead to leaflet folding, inversion, and displacement toward the left atrium.
Prolapsed mitral valves are classified into several subtypes, based on leaflet thickness, concavity, and type of connection to the mitral annulus. Subtypes can be described as classic, nonclassic, symmetric, asymmetric, flail, or non-flail.
All measurements below refer to adult patients; applying them to children may be misleading.
Classic versus nonclassic 
Prolapse occurs when the mitral valve leaflets are displaced more than 2 mm above the mitral annulus high points. The condition can be further divided into classic and nonclassic subtypes based on the thickness of the mitral valve leaflets: up to 5 mm is considered nonclassic, while anything beyond 5 mm is considered classic MVP.
Symmetric versus asymmetric 
Classical prolapse may be subdivided into symmetric and asymmetric, referring to the point at which leaflet tips join the mitral annulus. In symmetric coaptation, leaflet tips meet at a common point on the annulus. Asymmetric coaptation is marked by one leaflet displaced toward the atrium with respect to the other. Patients with asymmetric prolapse are susceptible to severe deterioration of the mitral valve, with the possible rupture of the chordae tendineae and the development of a flail leaflet.
Flail versus non-flail 
Asymmetric prolapse is further subdivided into flail and non-flail. Flail prolapse occurs when a leaflet tip turns outward, becoming concave toward the left atrium, causing the deterioration of the mitral valve. The severity of flail leaflet varies, ranging from tip eversion to chordal rupture. Dissociation of leaflet and chordae tendineae provides for unrestricted motion of the leaflet (hence "flail leaflet"). Thus patients with flail leaflets have a higher prevalence of mitral regurgitation than those with the non-flail subtype.
Echocardiography is the most useful method of diagnosing a prolapsed mitral valve. Two- and three-dimensional echocardiography are particularly valuable as they allow visualization of the mitral leaflets relative to the mitral annulus. This allows measurement of the leaflet thickness and their displacement relative to the annulus. Thickening of the mitral leaflets >5 mm and leaflet displacement >2 mm indicates classic mitral valve prolapse.
Prior to the strict criteria for the diagnosis of mitral valve prolapse, as described above, the incidence of mitral valve prolapse in the general population varied greatly. Some studies estimated the incidence of mitral valve prolapse at 5 to 15 percent or even higher. One study suggested MVP in up to 38% of healthy teenagers.
Recent elucidation of mitral valve anatomy and the development of three-dimensional echocardiography have resulted in improved diagnostic criteria, and the true prevalence of MVP based on these criteria is estimated at 2-3%. As part of the Framingham Heart Study, for example, the prevalence of mitral valve prolapse in Framingham, MA was estimated at 2.4%. There was a near-even split between classic and nonclassic MVP, with no significant age or sex discrimination. MVP is observed in 7% of autopsies in the United States.
Risk factors 
MVP may occur with greater frequency in individuals with Ehlers-Danlos Syndrome, Marfan syndrome or polycystic kidney disease. Other risk factors include Graves disease and chest wall deformities such as pectus excavatum. For unknown reasons, MVP patients tend to have a low body mass index (BMI) and are typically leaner than individuals without MVP.
Rheumatic fever is common worldwide and responsible for many cases of damaged heart valves. Chronic rheumatic heart disease is characterized by repeated inflammation with fibrinous resolution. The cardinal anatomic changes of the valve include leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords. The recurrence of rheumatic fever is relatively common in the absence of maintenance of low dose antibiotics, especially during the first three to five years after the first episode. Heart complications may be long-term and severe, particularly if valves are involved. While rheumatic fever since the advent of routine penicillin administration for Strep throat has become less common in developed countries, in the older generation and in much of the less-developed world, valvular disease (including mitral valve prolapse, reinfection in the form of valvular endocarditis, and valve rupture) from undertreated rheumatic fever continues to be a problem.
In an Indian hospital between 2004 and 2005, 4 of 24 endocarditis patients failed to demonstrate classic vegetatations. All had rheumatic heart disease (RHD) and presented with prolonged fever. All had severe eccentric mitral regurigitation (MR). (One had severe aortic regurgitation (AR) also.) One had flail posterior mitral leaflet (PML).
Signs and symptoms 
In contrast to most other heart murmurs, the murmur of mitral valve prolapse is accentuated by standing and valsalva maneuver (earlier systolic click and longer murmur) and diminished with squatting (later systolic click and shorter murmur). The only other heart murmur that follows this pattern is the murmur of hypertrophic cardiomyopathy. A MVP murmur can be distinguished from a hypertrophic cardiomyopathy murmur by 1) the presence of a mid-systolic click which is virtually diagnostic of MVP, and 2) the fact that hand grip maneuver intensifies the murmur of MVP and diminishes the murmur of hypertrophic cardiomyopathy. The hand grip maneuver also diminishes the duration of the murmur and delays the timing of the mid-systolic click. Hand grip maneuver increases total peripheral resistance (afterload) and therefore increases back pressure on the mitral valve resulting in a more intense murmur.
Both valsalva maneuver and standing decrease venous return to the heart thereby decreasing left ventricular diastolic filling (preload) and causing more laxity on the chordae tendineae. This allows the mitral valve to prolapse earlier in systole, leading to an earlier systolic click (i.e. closer to S1), and a longer murmur.
Mitral valve prolapse syndrome 
Historically, the term mitral valve prolapse syndrome has been applied to MVP associated with palpitations, atypical chest pain, dyspnea on exertion, low body mass index, and electrocardiogram abnormalities in the setting of anxiety, syncope, low blood pressure, and other signs suggestive of autonomic nervous system dysfunction.
Occasionally, supraventricular arrhythmias observed in MVP are associated with increased parasympathetic tone.
Mitral regurgitation 
Mitral valve prolapse is frequently associated with mild mitral regurgitation, where blood aberrantly flows from the left ventricle into the left atrium during systole. In the United States, MVP is the most common cause of severe, non-ischemic mitral regurgitation. This is occasionally due to rupture of the chordae tendineae that support the mitral valve.
Sudden death 
The MVP complications mitral regurgitation and congestive heart failure may, in turn, cause arrhythmias and atrial fibrillation that may progress and lead to sudden death. However, there is no evidence that a prolapsed valve itself contributes to such arrythmias.
Generally, MVP is benign. However, MVP patients with a murmur, not just an isolated click, have an increased mortality rate of 15-20%. The major predictors of mortality are the severity of mitral regurgitation and the ejection fraction.
Individuals with mitral valve prolapse, particularly those without symptoms, often require no treatment. Treatment with magnesium supplements may help reduce symptoms of MVP. Those with mitral valve prolapse and symptoms of dysautonomia (palpitations, chest pain) may benefit from beta-blockers (e.g., propranolol). Patients with prior stroke and/or atrial fibrillation may require blood thinners, such as aspirin or warfarin. In rare instances when mitral valve prolapse is associated with severe mitral regurgitation, mitral valve repair or surgical replacement may be necessary. Mitral valve repair is generally considered preferable to replacement. Current ACC/AHA guidelines promote repair of mitral valve in patients before symptoms of heart failure develop. Symptomatic patients, those with evidence of diminished left ventricular function, or those with left ventricular dilatation need urgent attention.
Natural therapies may include a natural diet higher in fat, red meat (see Nutritional Typing), probiotics, mineral-rich water, magnesium-rich foods, and avoiding enriched foods/supplements that are mineral antagonists (e.g., iron). Avoid sugar, a refined carbohydrate diet, and eat moderate amounts of complex carbohydrates with proteins, as well as naturally saturated fats, and nutrient-dense foods. Supplements may include: magnesium oxide or magnesium citrate (150-200 mg. two-three times daily); L-carnitine (500-1,000 mg. two-three times daily); Acetyl-l-carntine (120 mg. three times daily); Co-enzyme Q10 (60-120 mg/day); B vitamins (Vitamins B1 (thiamine) 100 mg./day; vitamin B3 (niacin) 50 mg./day; Vitamin B6 (pyridoxine) 50 mg./day; Inositol 3-6 grams/day.
If needed, natural relaxants are Kava (Piper methysticum) 100-200 milligrams standardized kava lactones per day); Valerian (heliotrope) 2-10 ml. tincture valerian up to every two hours; hops 0.5-1 gram of powder, or 2-4 ml. tincture as needed. .
Prevention of infective endocarditis 
Individuals with MVP are at higher risk of bacterial infection of the heart, called infective endocarditis. This risk is approximately three- to eightfold the risk of infective endocarditis in the general population. Until 2007, the American Heart Association recommended prescribing antibiotics before invasive procedures, including those in dental surgery. Thereafter, they concluded that "prophylaxis for dental procedures should be recommended only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from infective endocarditis."
Many organisms responsible for endocarditis are slow-growing and may not be easily identified on routine blood cultures (these fastidious organisms require special culture media to grow). These include the HACEK organisms, which are part of the normal oropharyngeal flora and are responsible for perhaps 5 - 10% of infective endocarditis affecting native valves. It is important when considering endocarditis to keep these organisms in mind.
- Hayek E, Gring CN, Griffin BP (2005). "Mitral valve prolapse". Lancet 365 (9458): 507–18. doi:10.1016/S0140-6736(05)17869-6. PMID 15705461.
- Barlow JB, Bosman CK (February 1966). "Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome". Am. Heart J. 71 (2): 166–78. doi:10.1016/0002-8703(66)90179-7. PMID 4159172.
- Criley JM, Lewis KB, Humphries JO, Ross RS (July 1966). "Prolapse of the mitral valve: clinical and cine-angiocardiographic findings". Br Heart J 28 (4): 488–96. doi:10.1136/hrt.28.4.488. PMC 459076. PMID 5942469.
- Playford, David; Weyman, Arthur (2001). "Mitral valve prolapse: time for a fresh look". Reviews in Cardiovascular Medicine 2 (2): 73–81. PMID 12439384.
- Levy D, Savage D. (1987). "Prevalence and clinical features of mitral valve prolapse". Am Heart J 113 (5): 1281–90. doi:10.1016/0002-8703(87)90956-2. PMID 3554946.
- Warth DC, King ME, Cohen JM, Tesoriero VL, Marcus E, Weyman AE (May 1985). "Prevalence of mitral valve prolapse in normal children". Journal of the American College of Cardiology 5 (5): 1173–7. doi:10.1016/S0735-1097(85)80021-8. PMID 3989128.
- Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. (1999). "Prevalence and clinical outcome of mitral-valve prolapse". N Engl J Med 341 (1): 1–7. doi:10.1056/NEJM199907013410101. PMID 10387935.
- Mitral Valve Prolapse at eMedicine
- "Related Disorders: Mitral Valve Prolapse". Archived from the original on 2007-02-25. Retrieved 2007-07-11.
- Lumiaho, A; Ikäheimo, R; Miettinen, R; Niemitukia, L; Laitinen, T; Rantala, A; Lampainen, E; Laakso, M et al. (2001). "Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1.". American journal of kidney diseases 38 (6): 1208–16. doi:10.1053/ajkd.2001.29216. PMID 11728952.
- "Mitral Valve Prolapse Overview".
- "Pectus Excavatum".
- Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. ISBN 0-7216-0187-1.
- NLM/NIH: Medline Plus Medical Encyclopedia: Rheumatic fever
- S Venkatesan, et al. (Sep-Oct 2007). "Can we diagnose Infective endocarditis without vegetation ?". Indian Heart Journal 59 (5).
- Grewe, K. (1988). Differentiation of cardiac murmurs by dynamic auscultation.Current Problems in Cardiology, 13, 673–721.
- Tanser, Paul H. (reviewed Mar 2007). "Mitral Valve Prolapse", The Merck Manuals Online Medical Library, Retrieved 2011-01-08.
- Terechtchenko L, Doronina SA, Pochinok EM, Riftine A. (2003). "Autonomic tone in patients with supraventricular arrhythmia associated with mitral valve prolapse in young men". Pacing Clin Electrophysiol 26 (1 Pt 2): 444–6. doi:10.1046/j.1460-9592.2003.00067.x. PMID 12687863.
- Kolibash AJ (1988). "Progression of mitral regurgitation in patients with mitral valve prolapse". Herz 13 (5): 309–17. PMID 3053383.
- Fogoros, Richard N. "Mitral Valve Prolapse (MVP)". Heart Disease. About.com. Retrieved 2007-07-11.
- Rodgers, Ellie (May 11, 2004). "Mitral Valve Regurgitation". Healthwise, on Yahoo. Retrieved 2007-07-11.
- "Mitral valve prolapse". Mayo Clinic.
- Lichodziejewska, B; Kłoś, J; Rezler, J; Grudzka, K; Dłuzniewska, M; Budaj, A; Ceremuzyński, L (1997). "Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation.". The American journal of cardiology 79 (6): 768–72. doi:10.1016/S0002-9149(96)00865-X. PMID 9070556.
- Natural Therapies for Mitral Valve Prolapse by Ronald Hoffman (Jan 11, 1999)
- Wilson W, Taubert KA, Gewitz M, et al. (2007). "Prevention of infective endocarditis: guidelines from the American Heart Association" (PDF). Journal of the American Dental Association (1939) 138 (6): 739–45, 747–60. PMID 17545263.
- Barlow JB, Bosman CK. (1966). "Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome". Am Heart J 71 (2): 166–78. doi:10.1016/0002-8703(66)90179-7. PMID 4159172.